Arjun Natesan - Ultragenyx Vice Research
| RARE Stock | USD 48.13 0.77 1.63% |
Executive
Arjun Natesan is Vice Research of Ultragenyx
| Address | 60 Leveroni Court, Novato, CA, United States, 94949 |
| Phone | 415 483 8800 |
| Web | https://www.ultragenyx.com |
Ultragenyx Management Efficiency
The company has return on total asset (ROA) of (0.2412) % which means that it has lost $0.2412 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8998) %, meaning that it created substantial loss on money invested by shareholders. Ultragenyx's management efficiency ratios could be used to measure how well Ultragenyx manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.49. At present, Ultragenyx's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 20.3 M, whereas Other Current Assets are forecasted to decline to about 34.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gil Golden | United Therapeutics | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| John Northcott | Arvinas | 46 | |
| Jan Smith | Revolution Medicines | N/A | |
| Randy Teel | Arvinas | 44 | |
| PharmD MBA | Incyte | 66 | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| JD Esq | Alnylam Pharmaceuticals | 71 | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Michael Morrissey | Incyte | 60 | |
| Indrani JD | Alnylam Pharmaceuticals | 51 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
Management Performance
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.24 |
Ultragenyx Leadership Team
Elected by the shareholders, the Ultragenyx's board of directors comprises two types of representatives: Ultragenyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ultragenyx. The board's role is to monitor Ultragenyx's management team and ensure that shareholders' interests are well served. Ultragenyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ultragenyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arjun Natesan, Vice Research | ||
| Vimal Srivastava, Senior Management | ||
| Aaron Olsen, Senior Finance | ||
| Paul JD, Vice Property | ||
| Dennis Huang, Chief Technical Operations Officer and Sr. VP | ||
| Theodore Huizenga, Corporate VP | ||
| Erik Harris, Executive Vice President and Chief Commercial Officer | ||
| Camille MD, Chief VP | ||
| Erik MBA, Executive Officer | ||
| Alison Skrinar, Vice Evaluation | ||
| Danielle Keatley, Senior Communications | ||
| Samuel Wadsworth, Chief Therapy | ||
| Ernie Meyer, Chief VP | ||
| Karah JD, Chief Affairs | ||
| John II, Chief Sciences | ||
| Thomas Kassberg, Chief Bus. Officer and Sr. VP | ||
| Eric MD, Chief VP | ||
| Howard Horn, Executive CFO |
Ultragenyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ultragenyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (1.07) % | ||||
| Operating Margin | (0.95) % | ||||
| Current Valuation | 3.79 B | ||||
| Shares Outstanding | 92.34 M | ||||
| Shares Owned By Insiders | 3.62 % | ||||
| Shares Owned By Institutions | 97.51 % | ||||
| Number Of Shares Shorted | 3.35 M | ||||
| Price To Earning | (6.90) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.45) | Revenue Per Share 6.015 | Quarterly Revenue Growth 0.423 | Return On Assets (0.24) | Return On Equity (2.90) |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.